India, April 15 -- Nexalin Technology, Inc. (NXL) announced progress in its U.S. regulatory pathway for Alzheimer's disease following a series of high-level meetings with the U.S. Food and Drug Administration (FDA) and international experts.
The company is developing its non-invasive Deep intracranial Frequency Stimulation (DIFS) technology as a drug-free approach to reduce Alzheimer's symptoms and cognitive decline. During a recent FDA Q-Submission meeting, regulators provided guidance on clinical trial design, including primary and secondary endpoints to measure treatment response in Alzheimer's patients. Nexalin plans to submit an amended application in the second quarter of 2026.
The strategy builds on extensive real-world neurostimul...